Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Interferon beta for multiple sclerosis

J F Connelly1

  • 1Drug Information Service Center, North Carolina Baptist Hospitals, Winston-Salem 27157.

The Annals of Pharmacotherapy
|May 1, 1994
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Hyperammonaemia due to ornithine transcarbamylase deficiency.

Archives of disease in childhood·2010
Same author

Suxamethonium-induced hyperkalaemia 6 weeks after chemoradiotherapy in a patient with rectal carcinoma.

British journal of anaesthesia·2007
Same author

Newborn screening for congenital hypothyroidism, Victoria, Australia, 1977-1997. Part 1: The screening programme, demography, baseline perinatal data and diagnostic classification.

Journal of pediatric endocrinology & metabolism : JPEM·2002
Same author

Newborn screening for congenital hypothyroidism, Victoria, Australia, 1977-1997. Part 2: Treatment, progress and outcome.

Journal of pediatric endocrinology & metabolism : JPEM·2002
Same author

Publication rates of abstracts from two pharmacy meetings.

The Annals of pharmacotherapy·2000
Same author

Distribution plan for immune globulin intravenous during a shortage.

American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists·1999
Same journal

Severe Phototoxic Skin Reaction Associated With Vandetanib: Implications for Pharmaceutical Care.

The Annals of pharmacotherapy·2026
Same journal

Efficacy and Safety of Oral PCSK9 Inhibitors in Adults With Hypercholesterolemia: An Updated Systematic Review and Meta-Analysis of RCTs.

The Annals of pharmacotherapy·2026
Same journal

RSVpreF: A Vaccine for the Respiratory Syncytial Virus.

The Annals of pharmacotherapy·2026
Same journal

Severe Acute Hepatitis Induced by Combined Rosuvastatin and Ticagrelor Therapy Post-PCI: The Challenges of Multi-Drug DILI Diagnosis.

The Annals of pharmacotherapy·2026
Same journal

Modified vs Full Lead-in Dose Apixaban and Rivaroxaban for Treatment of Acute Venous Thromboembolism.

The Annals of pharmacotherapy·2026
Same journal

A Comparison of Phenobarbital Dosing Strategies for the Treatment of Alcohol Withdrawal Syndrome.

The Annals of pharmacotherapy·2026
See all related articles

Interferon beta-1b (IFN beta ser) offers a new treatment for relapsing-remitting multiple sclerosis (RRMS), improving exacerbation rates and reducing disease burden. While not a cure, it

Area of Science:

  • Neuroscience
  • Immunology
  • Pharmacology

Background:

  • Multiple Sclerosis (MS) is a chronic neurological disease.
  • Relapsing-remitting MS (RRMS) is the most common form.
  • Limited treatment options were available for RRMS previously.

Purpose of the Study:

  • To review the efficacy and safety of interferon beta-1b (IFN beta ser) for RRMS.
  • To discuss therapeutic and economic considerations of IFN beta ser.
  • To provide an overview of IFN beta ser's pharmacology, clinical trials, and dosage.

Main Methods:

  • Literature search of MEDLINE for clinical trials and reviews.
  • Inclusion of trials with subcutaneous and intrathecal administration of interferon beta.
  • Review of toxicology data from the oncology population.

Related Experiment Videos

Main Results:

  • Interferon beta-1b (IFN beta ser) is FDA-approved for RRMS treatment.
  • IFN beta ser reduced annual exacerbation rates and improved the proportion of exacerbation-free patients.
  • Significant reduction in the burden of central nervous system disease was observed, though no changes were noted on specific disability scales.

Conclusions:

  • Interferon beta-1b (IFN beta ser) is a well-tolerated treatment for RRMS.
  • Patients with RRMS showed significant improvements in exacerbation rates and disease burden.
  • IFN beta ser represents a significant advancement in RRMS treatment, though further research is needed.